Advertisement

Development of candidates for new type 2 and type 3 oral poliovirus recombinant vaccines

  • M. Kohara
  • A. Nomoto

Summary

A number of recombinants between the virulent Mahoney and attenuated Sabin 1 strains of type 1 polioviruses were constructed. Results of biological tests including the monkey neurovirulence test on there recombinant viruses indicated that major determinants of the genome. The viral capsid proteins that contribute to viral antigenicity and immunogenicity, had a little correlation with the neurovirulence or attenuation phenotype of the virus. These results suggested that more safer vaccine strains of the Sabin type 2 and type 3 viruses can be con structed by replacing the sequence of viral capsid proteins of the Sabin 1 poliovirus by the corresponding genome sequences of the Sabin type 2 and type 3. Accordingly, we constructed recombinant viruses between the Sabin type 1 and type 2 or type 3, designated PV1/2(SS)BB and PVl/3(SS)BN, respectively, as candidates for type 2 and type 3 oral poliovirus vaccines. These recombinant viruses had antigenicity and immunogenicity of type 2 and type 3 polioviruses, respectively. The monkey neurovirulence tests and in vitro phenotypic marker tests of these recombinant virsuses indicate that PV1/2(SS)BB and PV1/3(SS)BN are possible candidates for new strain of type 2 and type 3 oral poliovirus vaccine.

Keywords

Vaccine Strain Recombinant Virus Oral Poliovirus Vaccine Viral Capsid Protein Live Vaccine Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sabin AB, Boulger LR (1973) History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1: 115–118CrossRefGoogle Scholar
  2. 2.
    Melnick JL (1984) Live attenuated oral poliovirus vaccine. Rev Infect Dis 6 [Suppl]: 323–327CrossRefGoogle Scholar
  3. 3.
    Kew OM, Nottay BK, Hatch MH, Nakano JH, Obijeski JF (1981) Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J Gen Virol 56:337–347PubMedCrossRefGoogle Scholar
  4. 4.
    Minor PD (1982) Characterization of strains of type 3 poliovirus by oligonucleotide map ping. J Gen Virol 59: 307–317PubMedCrossRefGoogle Scholar
  5. 5.
    Racaniello VR, Baltimore D (1981) Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214: 916–919PubMedCrossRefGoogle Scholar
  6. 6.
    Nomoto A, Omata T, Toyoda H, Kuge S, Horie H, Kataoka Y ,Genba Y, Nakano Y, Imura N (1982) Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci USA 79: 5793–5797PubMedCrossRefGoogle Scholar
  7. 7.
    Omata T, Kohara M, Kuge S ,Komatsu T ,Abe S, Semler BL, Kameda A, Itoh H ,Arita M, Wimmer E, Nomoto A (1986). Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol 58: 348–358PubMedGoogle Scholar
  8. 8.
    Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A (1988) A recombinant virus between the Sabin 1 and 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain. J Virol 62: 2828–2835PubMedGoogle Scholar
  9. 9.
    World Health Organization (1983) Requirements for poliomyelitis vaccine (oral). WHO Expert Committee on Biological Standardization. Annex 4. Tech Rep Ser 687: 107–165Google Scholar
  10. 10.
    Kawamura N ,Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A (1989) Determinants in the 5’ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 63: 1302–1309PubMedGoogle Scholar
  11. 11.
    Evans DMA, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel, J.V.Jr. (1985). Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314: 548–550PubMedCrossRefGoogle Scholar
  12. 12.
    Ren R, Moss EG, Racaniello VR (1991) Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 65: 1377–1382PubMedGoogle Scholar
  13. 13.
    Nomoto A, Iizuka N, Kohara M, and Arita M (1988) Strategy for construction of live picornavirus vaccines. Vaccine 6: 134–137.PubMedCrossRefGoogle Scholar
  14. 14.
    Kohara M, Abe S, Kuge S, Semler BL, Komatsu T, Arita M, Itoh H, Nomoto A (1986) An infectious cDNA clone of the poliovirus Sabin strain could be used as a stable repository and inoculum for the oral polio live vaccine. Virology 151: 21–30PubMedCrossRefGoogle Scholar
  15. 15.
    Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S (1982) Rapid evolution of RNA genomes. Science 215: 1577–1585PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • M. Kohara
    • 1
  • A. Nomoto
    • 1
    • 2
  1. 1.Department of MicrobiologyThe Tokyo Metropolitan Institute of Medical ScienceBunkyo-ku, TokyoJapan
  2. 2.Department of Microbiology, The Institute of Medical ScienceThe University of TokyoMinato-ku, TokyoJapan

Personalised recommendations